IP Library Granted Patent US 8,975,297
Granted Patent B2
US 8,975,297 · App. 14/216,664 · Granted Mar 10, 2015

3-methanesulfonylpropionitrile for treating inflammation and pain

Inventor: Joseph St. Laurent (Lakeville, MA)
Assignee: Olatec Industries LLC
C07C317/28A61K9/0014A61K9/06A61K31/275A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,975,297
App. No.
14/216,664
Granted
Mar 10, 2015
Kind
B2
Abstract

The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Claims (6)

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified compound of 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, wherein the composition is in an oral form of tablets, capsules, or syrups.

2. The pharmaceutical composition of claim 1 , wherein the compound is at least 90% (w/w) pure.

3. The pharmaceutical composition of claim 1 , wherein the compound is at least 95% (w/w) pure.

4. The pharmaceutical composition of claim 1 , wherein the oral form is a tablet.

5. The pharmaceutical composition of claim 4 , where the pharmaceutically acceptable carrier is selected from the group consisting of: carboxymethylcellulose, cellulose, ethylcellulose, hydroxypropylmethylcellulose, methylcellulose, karaya gum, starch, starch and tragacanth gum, poly(acrylic acid), and polyvinylpyrrolidone.

6. The pharmaceutical composition of claim 1 , wherein the oral form is a capsule.

Assignments (2)
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
CHANGE OF NAME Recorded Mar 18, 2016
From: OLATEC INDUSTRIES LLC
To: OLATEC THERAPEUTICS LLC
Reel/Frame 038177/0824 →
Continuity (4)
Continuation 13759676 · Feb 5, 2013
Division 13324777 · Dec 13, 2011
Provisional Application 61423485 · Dec 15, 2010
Related Publication 20140228433A1 · Aug 14, 2014